In my previous article, I explained why I felt the new Trump administration may be a positive for Pfizer (NYSE:PFE). But an investor need not only depend on these probable one-time windfall gains while putting their money in this stock. Besides having a solid and well-diversified drug portfolio, Pfizer also boasts of having some of the most promising investigational therapies in its research pipeline. Today, I plan to specifically focus on the company's oncology drugs that have a potential to deliver solid returns in 2017. These drugs form the core reasons why I believe in Pfizer's stock performance in 2017. If you want to know my rationale for being bullish on this stock since 2016, please read Should You Buy Pfizer Now? as well as Top 4 Reasons Why Pfizer Continues To Be A Buy In 2016.
Ibrance currently dominates the newly diagnosed HR+ and HER2- metastatic breast cancer segment in USA
